- Companies
- Co-Diagnostics
Co-Diagnostics Valuation Multiples
Co-Diagnostics is valued at $2M as of November 2026, a 0.6x revenue multiple. In the last 12 months, Co-Diagnostics revenue was $649K.
Co-Diagnostics Overview
About Co-Diagnostics
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Founded
2013
HQ
Employees
115
Website
Financials (LTM)
EV
$372K
Valuation Multiples
Start free trialCo-Diagnostics Financials
Co-Diagnostics reported last 12-month revenue of $649K.
In the same LTM period, Co-Diagnostics generated had net loss of ($31M).
Revenue (LTM)
Co-Diagnostics P&L
In the most recent fiscal year, Co-Diagnostics reported revenue of $622K and EBITDA of ($48M).
Co-Diagnostics is unprofitable as of last fiscal year, with gross margin of 64%, EBITDA margin of (7662%), and net margin of (7534%).
Financial data powered by Morningstar, Inc.
Co-Diagnostics Stock Performance
Co-Diagnostics has current market cap of $2M, and enterprise value of $372K.
Market Cap Evolution
Co-Diagnostics' stock price is $0.25.
Co-Diagnostics share price decreased by 31.3% in the last 30 days, and by 97.7% in the last year.
Co-Diagnostics has an EPS (earnings per share) of $-5.32.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $372K | $2M | -8.0% | -31.3% | -79.8% | -97.7% | $-5.32 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCo-Diagnostics Valuation Multiples
Co-Diagnostics trades at 0.6x EV/Revenue multiple, and (0.0x) EV/EBITDA.
EV / Revenue (LTM)
Co-Diagnostics Financial Valuation Multiples
As of November 7, 2026, Co-Diagnostics has market cap of $2M and EV of $372K.
Co-Diagnostics has a P/E ratio of (0.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Co-Diagnostics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Co-Diagnostics Margins & Growth Rates
Co-Diagnostics grew revenue by 5% but net profit decreased by 39% in the last fiscal year.
In the most recent fiscal year, Co-Diagnostics reported gross margin of 64%, EBITDA margin of (7662%), and net margin of (7534%).
Co-Diagnostics Margins
Co-Diagnostics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Co-Diagnostics Operational KPIs
Co-Diagnostics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Co-Diagnostics Competitors
Co-Diagnostics competitors include PEPTONIC medical, IMD Companies, Invent Medic Sweden, Bluelinea, Euroinvestment, Bio View, INVO Fertility, Zenicor Medical Systems, VibroSense Dynamics and Nuwellis.
Most Co-Diagnostics public comparables operate across Medical Devices, Laboratory Services, HealthTech and DeepTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $2M | ($1M) | 1.4x | - | (1.6x) | - | |||
| - | - | - | - | - | - | |||
| $755K | ($476K) | 2.2x | - | (3.4x) | - | |||
| $12M | $723K | 0.5x | - | 8.2x | - | |||
| - | ($1K) | - | - | (2564.0x) | - | |||
| $6M | ($2M) | 0.0x | - | (0.1x) | - | |||
| $7M | ($4M) | 0.5x | 0.5x | (0.9x) | - | |||
| $3M | $678K | 1.0x | - | 4.4x | - | |||
This data is available for Pro users. Sign up to see all Co-Diagnostics competitors and their valuation data. Start Free Trial | ||||||||
Acquisitions by Co-Diagnostics
Co-Diagnostics has acquired 3 companies to date.
Last acquisition by Co-Diagnostics was on December 23rd 2021. Co-Diagnostics acquired Idaho Molecular for $21M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Co-Diagnostics
| Description | Idaho Molecular is a Meridian-based biotechnology firm developing diagnostic devices for labs, hospitals, and research facilities. The company produces molecular testing platforms for infectious diseases and genetic analysis, enabling rapid data-driven decisions. Idaho Molecular's solutions integrate PCR technology and cloud-based reporting for clinical applications. | Advanced Conceptions is a medical device company specializing in diagnostic and therapeutic tools for reproductive health. Mountain View, California-based, it develops intrauterine devices and fertility assessment systems to improve conception rates and embryo selection. | MEDCIS Pathlabs India Pvt. Ltd. is a clinical investigation laboratory providing diagnostic services in pathology, biochemistry, microbiology, and histopathology across India. Hyderabad-based, the company integrates global diagnostic technologies to support physician decision-making with accurate test reports in multiple medical branches. |
| HQ Country | |||
| HQ City | Salt Lake City, UT | Salt Lake City, UT | Hyderabad |
| Deal Date | 23 Dec 2021 | 23 Dec 2021 | 5 Sep 2017 |
| Valuation | $21M | $36M | undisclosed |
| EV/Revenue | |||
| EV/EBITDA | |||
This data is available for Pro users. Sign up to see all Co-Diagnostics acquisitions and their M&A valuation multiples. Start Free Trial | |||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Co-Diagnostics
| Who are competitors of Co-Diagnostics? | Co-Diagnostics main competitors include PEPTONIC medical, IMD Companies, Invent Medic Sweden, Bluelinea, Euroinvestment, Bio View, INVO Fertility, Zenicor Medical Systems, VibroSense Dynamics, Nuwellis. |
See public comps similar to Co-Diagnostics
Lists including Co-Diagnostics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




